Detalhe da pesquisa
1.
Rivoceranib, a VEGFR-2 inhibitor, monotherapy in previously treated patients with advanced or metastatic gastric or gastroesophageal junction cancer (ANGEL study): an international, randomized, placebo-controlled, phase 3 trial.
Gastric Cancer
; 27(2): 375-386, 2024 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-38281295
2.
Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study.
Lancet Oncol
; 24(5): 483-495, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37080222
3.
Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 21(4): 393-422, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-37015332
4.
Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
J Natl Compr Canc Netw
; 20(2): 167-192, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35130500
5.
Outcomes on anti-VEGFR-2/paclitaxel treatment after progression on immune checkpoint inhibition in patients with metastatic gastroesophageal adenocarcinoma.
Int J Cancer
; 149(2): 378-386, 2021 07 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-33739449
6.
MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Future Oncol
; 17(10): 1155-1164, 2021 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-33263418
7.
Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer.
Support Care Cancer
; 29(2): 733-739, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-32447502
8.
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study.
Gastric Cancer
; 22(4): 828-837, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30911859
9.
First Report of Dramatic Tumor Responses with Ramucirumab and Paclitaxel After Progression on Pembrolizumab in Two Cases of Metastatic Gastroesophageal Adenocarcinoma.
Oncologist
; 23(7): 840-843, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29674442
10.
Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma.
Oncologist
; 23(9): 1004-e102, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29769385
11.
Ectopic fat accumulation in the pancreas and its biomarkers: A systematic review and meta-analysis.
Diabetes Metab Res Rev
; 33(8)2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28730683
12.
Central nervous system relapse in patients with untreated HER2-positive esophageal or gastroesophageal junction adenocarcinoma.
Int J Cancer
; 139(7): 1626-31, 2016 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27198655
13.
Relationship between pancreatic hormones and glucose metabolism: A cross-sectional study in patients after acute pancreatitis.
Am J Physiol Gastrointest Liver Physiol
; 311(1): G50-8, 2016 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27173509
14.
HER-2/neu gene amplification in relation to expression of HER2 and HER3 proteins in patients with esophageal adenocarcinoma.
Cancer
; 120(3): 415-24, 2014 Feb 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-24151090
15.
Advances in Immunotherapy in Esophagogastric Cancer.
Hematol Oncol Clin North Am
; 38(3): 599-616, 2024 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-38493074
16.
Life-threatening "hyper-progression" on immunotherapy revealed as pseudo-progression in DNA mismatch repair deficiency: a case report.
J Gastrointest Oncol
; 14(1): 435-441, 2023 Feb 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-36915442
17.
Risk stratification of postoperative cardiopulmonary toxicity after trimodality therapy for esophageal cancer.
Front Oncol
; 13: 1081024, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-36845682
18.
Understanding Suboptimal Response to Immune Checkpoint Inhibitors.
Adv Biol (Weinh)
; 7(4): e2101319, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35343107
19.
Impact of PD-1 Blockade in Nonresponders: Pitfalls and Promise.
Clin Cancer Res
; 28(15): 3173-3175, 2022 08 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-35671005
20.
Association of PD-L1 Expression and Other Variables With Benefit From Immune Checkpoint Inhibition in Advanced Gastroesophageal Cancer: Systematic Review and Meta-analysis of 17 Phase 3 Randomized Clinical Trials.
JAMA Oncol
; 8(10): 1456-1465, 2022 10 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36006624